F. Haderk

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

This study identifies PDK1 as a driver of osimertinib resistance in NSCLC, showing its inhibition sensitizes resistant cells and correlates with disease progression.

A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer

This study identifies a FAK-YAP signaling axis that drives drug-tolerant persister cells and residual disease in lung cancer, showing that inhibiting this axis improves tumor response to targeted therapies.

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

This study shows that RBM10 deficiency reduces EGFR inhibitor efficacy in EGFR mutant lung cancer by altering Bcl-x splicing and apoptosis, and that co-inhibiting Bcl-xL can overcome this resistance.

A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

The paper constructs a tyrosine kinase protein interaction map, revealing EGFR network oncogenesis in 19% of EGFR wild-type lung cancers, which is targetable with EGFR inhibitors.

Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing

This study uses longitudinal single-cell RNA sequencing to reveal therapy-induced adaptations in lung cancer, identifying cell state transitions and pathways associated with treatment response and resistance.